Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01745198 · ClinicalTrials.gov registry record
Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements
A clinical trial of Mild Cognitive Impairment and Alzheimers Disease, sponsored by Pamlab.
- Completed
- Registry status
- 121
- Enrollment target
- 1
- Study location
NCT01745198 is a study of Mild Cognitive Impairment and Alzheimers Disease that has completed, run by Pamlab. The registered enrollment target is 121 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01745198, a study of Mild Cognitive Impairment and Alzheimers Disease, has completed, sponsored by Pamlab.
- COMPLETED
- Registry status
- 121 participants
- Enrollment target
- 1
- Study location
Study Summary
In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition. The purpose of the current study is to expand the retrospective study dataset by prospectively collecting additional biomarker and imaging data.
Conditions Studied
Study Locations (1)
California
- Hoag Memorial Hospital - Newport Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01745198
The ClinicalTrials.gov registry entry for NCT01745198 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (90% lower). The listed sponsor is Pamlab, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT01745198 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01745198 about?
NCT01745198 is a clinical study titled "Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements". In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition. The purpose of the current study is to expand the retrospective study dataset by prospectively collecting additional biomarker and imaging data.
What is the current status of trial NCT01745198?
This trial is currently completed. The enrollment target is 121 participants. The study started on 2012-12. Estimated completion is 2014-06.
What conditions does trial NCT01745198 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment, Alzheimers Disease, Alzheimer's Disease Related Disorders.
Who is sponsoring clinical trial NCT01745198?
This trial is sponsored by Pamlab, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01745198 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.